VolitionRX (NYSEAMERICAN:VNRX) Stock Crosses Below 50-Day Moving Average of $0.00

Share on StockTwits

VolitionRX Ltd (NYSEAMERICAN:VNRX) shares passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.00 and traded as low as $2.99. VolitionRX shares last traded at $3.01, with a volume of 1,298 shares.

Several research firms recently issued reports on VNRX. Oppenheimer set a $5.00 target price on VolitionRX and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Maxim Group reissued a “buy” rating and set a $6.00 target price on shares of VolitionRX in a research note on Thursday, March 28th.

VolitionRX (NYSEAMERICAN:VNRX) last released its quarterly earnings results on Wednesday, May 8th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12).

In related news, Director Martin Charles Faulkes bought 70,731 shares of the stock in a transaction on Monday, June 10th. The shares were bought at an average cost of $3.02 per share, for a total transaction of $213,607.62. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

An institutional investor recently bought a new position in VolitionRX stock. Virtu Financial LLC purchased a new stake in VolitionRX Ltd (NYSEAMERICAN:VNRX) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 10,794 shares of the medical research company’s stock, valued at approximately $35,000.

WARNING: This article was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/4379940/volitionrx-nyseamericanvnrx-stock-crosses-below-50-day-moving-average-of-0-00.html.

VolitionRX Company Profile (NYSEAMERICAN:VNRX)

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.

Featured Article: Buyback

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MKM Partners Lowers ADTRAN  Price Target to $17.00
MKM Partners Lowers ADTRAN Price Target to $17.00
Apple  PT Raised to $180.00 at Nomura
Apple PT Raised to $180.00 at Nomura
Advaxis  Lowered to “Hold” at ValuEngine
Advaxis Lowered to “Hold” at ValuEngine
Zacks Investment Research Upgrades Atlas Air Worldwide  to “Hold”
Zacks Investment Research Upgrades Atlas Air Worldwide to “Hold”
Apple  Raised to “Outperform” at Raymond James
Apple Raised to “Outperform” at Raymond James
Zacks Investment Research Lowers Agilysys  to Hold
Zacks Investment Research Lowers Agilysys to Hold


© 2006-2019 Ticker Report